Intellia Therapeutics Reports Positive Longer-Term Phase 1 Data for Nexiguran Ziclumeran in ATTR Amyloidosis Cardiomyopathy

Reuters11-11

Intellia <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Reports Positive Longer-Term Phase 1 Data for Nexiguran Ziclumeran in ATTR Amyloidosis Cardiomyopathy

Intellia Therapeutics Inc. announced positive follow-up data from its ongoing Phase 1 clinical trial of nexiguran ziclumeran (nex-z), an investigational therapy for patients with transthyretin $(ATTR)$ amyloidosis with cardiomyopathy. The results were presented at the American Heart Association (AHA) Scientific Sessions 2025 in New Orleans. According to the company, a single dose of nex-z resulted in a rapid, deep, and durable reduction in serum transthyretin (TTR) levels, with stability or improvement in multiple markers of cardiomyopathy observed at 24 months. Nex-z was generally well tolerated, with the most common treatment-related adverse events being infusion-related reactions and transaminase elevations, none exceeding Grade 2. Deaths reported during the study were attributed to the progression of underlying cardiovascular disease. Longer-term safety data were consistent with previous reports from the Phase 1 trial.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Intellia Therapeutics Inc. published the original content used to generate this news brief on November 10, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2582802495?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-11 04:23","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2582802495","market":"nz","top_or_hot":-1,"title":"Intellia Therapeutics Reports Positive Longer-Term Phase 1 Data for Nexiguran Ziclumeran in ATTR Amyloidosis Cardiomyopathy","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Intellia <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Reports Positive Longer-Term Phase 1 Data for Nexiguran Ziclumeran in ATTR Amyloidosis Cardiomyopathy\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/NTLA\">Intellia Therapeutics Inc</a>. announced positive follow-up data from its ongoing Phase 1 clinical trial of nexiguran ziclumeran (nex-z), an investigational therapy for patients with transthyretin <a href=\"https://laohu8.com/S/ATTR\">$(ATTR)$</a> amyloidosis with cardiomyopathy. The results were presented at the American Heart Association (AHA) Scientific Sessions 2025 in New Orleans. According to the company, a single dose of nex-z resulted in a rapid, deep, and durable reduction in serum transthyretin (TTR) levels, with stability or improvement in multiple markers of cardiomyopathy observed at 24 months. Nex-z was generally well tolerated, with the most common treatment-related adverse events being infusion-related reactions and transaminase elevations, none exceeding Grade 2. Deaths reported during the study were attributed to the progression of underlying cardiovascular disease. Longer-term safety data were consistent with previous reports from the Phase 1 trial.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Intellia Therapeutics Inc. published the original content used to generate this news brief on November 10, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Intellia Therapeutics Reports Positive Longer-Term Phase 1 Data for Nexiguran Ziclumeran in ATTR Amyloidosis Cardiomyopathy</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIntellia Therapeutics Reports Positive Longer-Term Phase 1 Data for Nexiguran Ziclumeran in ATTR Amyloidosis Cardiomyopathy\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-11 04:23</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Intellia <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Reports Positive Longer-Term Phase 1 Data for Nexiguran Ziclumeran in ATTR Amyloidosis Cardiomyopathy\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/NTLA\">Intellia Therapeutics Inc</a>. announced positive follow-up data from its ongoing Phase 1 clinical trial of nexiguran ziclumeran (nex-z), an investigational therapy for patients with transthyretin <a href=\"https://laohu8.com/S/ATTR\">$(ATTR)$</a> amyloidosis with cardiomyopathy. The results were presented at the American Heart Association (AHA) Scientific Sessions 2025 in New Orleans. According to the company, a single dose of nex-z resulted in a rapid, deep, and durable reduction in serum transthyretin (TTR) levels, with stability or improvement in multiple markers of cardiomyopathy observed at 24 months. Nex-z was generally well tolerated, with the most common treatment-related adverse events being infusion-related reactions and transaminase elevations, none exceeding Grade 2. Deaths reported during the study were attributed to the progression of underlying cardiovascular disease. Longer-term safety data were consistent with previous reports from the Phase 1 trial.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Intellia Therapeutics Inc. published the original content used to generate this news brief on November 10, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251110:nNDLvd3S2:1","article_id":"2582802495","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2582802495","pubTimestamp":1762806214,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Intellia Therapeutics Inc. announced positive follow-up data from its ongoing Phase 1 clinical trial of nexiguran ziclumeran , an investigational therapy for patients with transthyretin  amyloidosis with cardiomyopathy. The results were presented at the American Heart Association  Scientific Sessions 2025 in New Orleans. According to the company, a single dose of nex-z resulted in a rapid, deep, and durable reduction in serum transthyretin  levels, with stability or improvement in multiple markers of cardiomyopathy observed at 24 months. Nex-z was generally well tolerated, with the most common treatment-related adverse events being infusion-related reactions and transaminase elevations, none exceeding Grade 2. Deaths reported during the study were attributed to the progression of underlying cardiovascular disease. Longer-term safety data were consistent with previous reports from the Phase 1 trial.Disclaimer: This news brief was created by Public Technologies  using generative artifici","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","BK4556":"基因编辑","BK4585":"ETF&股票定投概念","NTLA":"Intellia Therapeutics Inc","BK4588":"碎股","LU1861558580.USD":"日兴方舟颠覆性创新基金B","BK4535":"淡马锡持仓","LU1861559042.SGD":"日兴方舟颠覆性创新基金B SGD"},"translate_title":"Intellia Therapeutics报告Nexiguran Ziclumeran治疗ATTR淀粉样变性心肌病的积极长期1期数据","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NTLA":0.9},"content_text":"Intellia Therapeutics Reports Positive Longer-Term Phase 1 Data for Nexiguran Ziclumeran in ATTR Amyloidosis Cardiomyopathy\n    \n\nIntellia Therapeutics Inc. announced positive follow-up data from its ongoing Phase 1 clinical trial of nexiguran ziclumeran (nex-z), an investigational therapy for patients with transthyretin $(ATTR)$ amyloidosis with cardiomyopathy. The results were presented at the American Heart Association (AHA) Scientific Sessions 2025 in New Orleans. According to the company, a single dose of nex-z resulted in a rapid, deep, and durable reduction in serum transthyretin (TTR) levels, with stability or improvement in multiple markers of cardiomyopathy observed at 24 months. Nex-z was generally well tolerated, with the most common treatment-related adverse events being infusion-related reactions and transaminase elevations, none exceeding Grade 2. Deaths reported during the study were attributed to the progression of underlying cardiovascular disease. Longer-term safety data were consistent with previous reports from the Phase 1 trial.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Intellia Therapeutics Inc. published the original content used to generate this news brief on November 10, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport,express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2582802495","isCrawlerRequest":true}